Market's view on Centrica
Published on April 2024
- A stock watcher predicted a potential rally for CNA, citing strong performances by similar companies like Shell and BP.
- AlliancePharma has a record of long-term growth and has broadened its portfolio through acquisitions, with a dividend increase of 5%.
- Goldman Sachs increased Centrica’s price target from 190 to 195 pence, recommending a ‘buy’.
- A stock watcher noted strong performance against a falling market and anticipated a share price increase to 142p+.
- The dividend yield being only 2% was noted as insufficient to offset capital losses from investments.
- RBC downgraded Centrica to ‘sector perform’ with a new price target of 145 pence.
- A skeptic opinion was expressed about the current bullish sentiment, suggesting it’s too good to be true.
- Another stock watcher turned bearish on a company, citing concerns over management despite the low PE ratio and abundant cash reserves.
- A mention of abnormal trading volume indicated potential future movement in stock prices.
- Concerns were raised about potential downward pressure on stock prices despite recent large trading volumes.
- Dividend yield and price to book ratio statistics were provided, noting a shift from historic figures.
- A cautionary note was made regarding the potential impact of a Labour Government on UK businesses’ profitability.